Case Study Mrs. A Is A 71-Year-Old Widow With CHF And Osteo

Case Study Mrs. A is a 71 Year Old Widow With Chf And Osteoarthritis Wh

Case Study Mrs. A is a 71-year-old widow with congestive heart failure (CHF) and osteoarthritis who has recently exhibited unusual behavior. Her daughter is concerned about her mother's independence and is considering nursing home admission. The daughter fears Mrs. A may be developing a dementing illness. Over the last two to three months, Mrs. A has become confused, easily fatigued, and irritable. She also developed obsessive-compulsive behaviors, persistently complaining that her lace curtains are dirty and need frequent washing. She believed they appeared yellow-green or moldy. Her prescribed medications include furosemide 40 mg daily in the morning, digoxin 250 micrograms daily, paracetamol 500 mg 1-2 tablets every four hours as needed, piroxicam 20 mg at night, Mylanta suspension 20 ml as needed, and coloxyl 120 mg 1-2 tablets at night.

Sample Paper For Above instruction

The pharmacological management of Mrs. A presents several problematic issues, primarily related to polypharmacy, age-related pharmacokinetic changes, and potential drug interactions. Polypharmacy, defined as the use of five or more medications (Masnoon et al., 2017), is common among elderly patients with multimorbidity but significantly increases the risk of adverse outcomes, including drug interactions, adverse drug reactions, falls, hospitalizations, and mortality (Maher et al., 2021). Mrs. A's medication regimen includes drugs with overlapping adverse effect profiles, which warrants critical review and management to optimize her therapeutic outcomes and safety.

From a pharmacological perspective, furosemide is a loop diuretic used to manage CHF, but it may cause electrolyte imbalances, particularly hypokalemia (Hansen et al., 2020). Digoxin, used for heart failure or arrhythmias, carries a narrow therapeutic window and has interactions with other medications and electrolyte disturbances, notably hypokalemia (Roy et al., 2019). Paracetamol, despite being generally safe at therapeutic doses, requires caution, especially in older adults with potential hepatic impairment (García-García et al., 2020). Piroxicam, a nonsteroidal anti-inflammatory drug (NSAID), can cause renal impairment and exacerbate heart failure, particularly in the elderly (Haller et al., 2018). Mylanta, an antacid containing magnesium hydroxide, can affect electrolyte levels and kidney function, especially in concurrence with diuretics and NSAIDs. Coloxyl (docusate sodium) is a stool softener that can interact with other medications affecting electrolyte and fluid balance.

Pharmacokinetic changes in elderly individuals significantly influence drug disposition. These changes include decreased gastric acid secretion, altered gastrointestinal motility, increased body fat, decreased lean body mass, reduced total body water, and decreased serum albumin levels (Mangoni & Jackson, 2004). These alterations affect drug absorption, distribution, metabolism, and excretion. For instance, increased body fat can prolong the half-life of lipophilic drugs such as diazepam, leading to accumulation and prolonged effects. Decreased serum albumin may elevate free drug levels of highly protein-bound medications like phenytoin and digoxin, increasing toxicity risk.

Changes in hepatic and renal functions are especially critical as they directly impact drug metabolism and clearance. Hepatic metabolism via CYP enzymes generally decreases with age due to reduced liver size and blood flow (Maher et al., 2021). This decline can prolong the half-life of drugs metabolized by the liver, necessitating dosage adjustments. Renal function, frequently assessed by glomerular filtration rate (GFR), typically declines with age (Miller et al., 2016). The reduced renal clearance complicates dosing of renally excreted drugs like digoxin and diuretics, raising the risk for toxicity. Therefore, regular assessment of renal function via estimated GFR is essential in following dosing adjustments and preventing adverse effects (Matzke & James, 2016).

In Mrs. A's case, her complex medication regimen presents several risks. For example, both digoxin and piroxicam can increase serum potassium levels, heightening the risk of hyperkalemia, which can precipitate arrhythmias (Kumar & Clark, 2017). Paracetamol's hepatotoxic potential is usually minimal but may be exacerbated in the presence of compromised liver function, common in elderly patients (García-García et al., 2020). The combination of diuretics and NSAIDs, as seen with furosemide and piroxicam, can synergistically impair renal function, leading to acute kidney injury (Haller et al., 2018). Mylanta, containing magnesium hydroxide, could accumulate in the setting of decreased renal clearance, leading to magnesium toxicity, which manifests as neuromuscular and cardiac disturbances (Hansen et al., 2020).

Furthermore, potential drug interactions need careful consideration. Digoxin interacts with Mylanta by increasing its renal clearance, which might lower serum levels and reduce efficacy, or if kidney function declines, elevate toxicity risk (Roy et al., 2019). Similarly, combining NSAIDs like piroxicam with diuretics can diminish natriuretic effects, worsening CHF symptoms, and increasing electrolyte imbalances (Haller et al., 2018). These pharmacodynamic and pharmacokinetic interactions can be mitigated through careful monitoring and dose adjustments based on renal function, electrolytes, and clinical response.

Addressing these issues involves strategic medication review, regular laboratory monitoring, and patient education. Recommendations include regular assessment of serum electrolytes, renal function, and digoxin levels, especially considering age-related decline in organ function (Maher et al., 2021). Dose adjustments should be guided by renal function estimations, such as the CKD-EPI equation, to prevent toxicity. Alternative medications with lower interaction potential or better safety profiles for elderly patients should be considered, especially for osteoarthritis management. For example, topical NSAIDs or acetaminophen, with ongoing assessment, may be safer options than systemic NSAIDs in this context (García-García et al., 2020).

Polypharmacy, while often unavoidable in managing complex chronic conditions, poses significant risks for adverse events. Strategies to improve outcomes include comprehensive medication reconciliation, deprescribing unnecessary medications, and engaging patients in medication management and adherence education. In Mrs. A's case, a multidisciplinary approach involving pharmacists, physicians, and caregivers can optimize medication regimens, monitor adverse effects, and enhance safety. Pharmacist-led medication reviews have demonstrated effectiveness in reducing polypharmacy risks and improving clinical outcomes (Clyne et al., 2019). Patient education should emphasize understanding medication purposes, potential side effects, and the importance of adherence and reporting new symptoms.

References

  • Clyne, B., Bradley, C., Hughes, C. M., et al. (2019). Effectiveness of pharmacist-led interventions on chronic medication adherence in primary care: A systematic review. European Journal of Clinical Pharmacology, 75(3), 337–348.
  • García-García, P., Carrillo-García, M., & Gómez-Ríos, M. (2020). Paracetamol hepatotoxicity: Review of clinical cases and mechanisms. Revista de Gastroenterología de México, 85(2), 208–216.
  • Haller, C., Radstake, F., & Schellevis, F. (2018). NSAIDs and renal function in elderly patients: A review. Journal of Renal Nutrition, 28(3), 157–162.
  • Hansen, T. H., Jensen, L. T., & Nørgaard, K. (2020). Diuretics in elderly patients: Balance between efficacy and safety. Drugs & Aging, 37(2), 83–93.
  • Kumar, P., & Clark, M. (2017). Kumar & Clark's Clinical Medicine. Elsevier.
  • Mangoni, A. A., & Jackson, S. H. (2004). Age-related changes in pharmacokinetics and pharmacodynamics: Clinical implications. The Journal of Clinical Pharmacology, 44(12), 1105–1114.
  • Matzke, G., & James, M. (2016). Drug elimination and renal function in elderly patients. Nephrology Dialysis Transplantation, 31(3), 385–392.
  • Maher, D., Ailabouni, N., Mangoni, A. A., et al. (2021). Alterations in drug disposition in older adults: a focus on geriatric syndromes. Expert Opinion on Drug Metabolism & Toxicology, 17(1), 41–52.
  • Miller, R. P., Singh, R., & Jain, S. (2016). Renal function assessment in geriatric patients. Clinical Geriatrics, 24(5), 35–42.
  • Roy, A., Tiwari, S., & Khakhar, N. (2019). Digoxin toxicity: Pathophysiology, diagnosis, and management. Indian Journal of Pharmacology, 51(6), 343–347.

Related Assignments